Latest News
Deramiocel FDA Decision: Can Capricor Win Approval in Duchenne?
The deramiocel FDA decision is due by 22 November 2026. Deramiocel is Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has had a turbulent 16 months with it. A complete response letter (CRL) came in...
Latest News
Weekly News Roundup | 2 November 2026
Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...
ESMO 2026: The Five Results That Could Change Cancer Treatment
ESMO 2026 closed in Madrid on 27 October after five days of practice-shaping data. The most closely watched results came in three Presidential Symposia, which carried twelve late-breaking phase 3 trials. Five of them stand out for their potential to change how...
What Are You Signing When the AI Wrote the Note?
Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...
Peptide Compounding Explained: What the HHS Six-Peptide Policy Allows
Peptide compounding in the United States has entered a new phase. The Department of Health and Human Services (HHS) will not act against compounders of six unapproved peptides, within strict conditions. The peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Digital Health and the Reordering of Life Sciences Commercialization
It’s been an extraordinary two years for anyone working in pharma commercialization, with the macro environment shifting meaningfully under the feet of all those sitting on the commercial side of pharma or building in digital health with pharma partnership...
From Data to Decisions: The Next Frontier in Diabetic Foot Care
If you are not aware of the statistics on diabetic limb loss, they deserve your attention. Prevention is an absolute necessity. We call this diabetic foot care, and the way podiatrists utilize these opportunities is moving into a more data-rich era. Remote...
Expedited IND Pilot Opens as UK Fast Track Bars First-in-Human
The US Food and Drug Administration began accepting applications on 15 September 2026 for its expedited IND pilot. The programme is a key component of Operation TrialBlazer, according to the agency. The Department of Health and Human Services announced that initiative...
Why Pharmaceutical Quality Cannot Be Tested Into a Product
In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...
Fifty Patients, No Registry: MVA Research Meets in London
Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...
Semaglutide Patent Expiry: What Generics Did to Prices
The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...
AI as a Research Partner for the Overstretched Life Sciences
Generative AI can lift the administrative weight of literature reviews and manuscript drafting, but only when it stays grounded in evidence and firmly under human control. The problem we know too well Every clinician who also publishes lives with a quiet collision. On...
FDA Clears First Glioma PET Imaging Drug After 2025 Rejection
The Food and Drug Administration has approved Pixclara, a glioma PET imaging drug from Telix Pharmaceuticals. Telix announced the decision in its approval announcement on 14 September 2026. The active ingredient is floretyrosine F 18, also written as 18F-FET. Telix...
Medical AI Is Getting Better. Why Is Diagnosis Getting Harder?
A radiologic study today rarely arrives alone. It comes wrapped in automated detection flags, quantitative lesion scores, an AI-drafted report, historical imaging, EHR clinical notes, and subspecialty consult requests. What it does not come wrapped in is medical AI...
Stellaromics Expands Pyxa Adoption Across the U.S. and Europe
Stellaromics Expands Pyxa® Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and Europe Icahn School of Medicine at Mount Sinai, CNAG, Karolinska Institutet, and Stanford University will apply 3D spatial multi-omics across...
Freeze-Dried Does Not Mean Pathogen-Free
Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...
Why AI Governance in Life Sciences Can’t Wait for Regulatory Clarity
The regulatory picture for AI governance in life sciences just got more confusing, not less. In June 2026, the European Union's Digital Omnibus package pushed back the EU AI Act's compliance deadline for stand-alone high-risk AI systems from August 2026 to December...
Digital Health and the Reordering of Life Sciences Commercialization
It’s been an extraordinary two years for anyone working in pharma commercialization, with the macro environment shifting meaningfully under the feet of all those sitting on the commercial side of pharma or building in digital health with pharma partnership...
From Data to Decisions: The Next Frontier in Diabetic Foot Care
If you are not aware of the statistics on diabetic limb loss, they deserve your attention. Prevention is an absolute necessity. We call this diabetic foot care, and the way podiatrists utilize these opportunities is moving into a more data-rich era. Remote...
Expedited IND Pilot Opens as UK Fast Track Bars First-in-Human
The US Food and Drug Administration began accepting applications on 15 September 2026 for its expedited IND pilot. The programme is a key component of Operation TrialBlazer, according to the agency. The Department of Health and Human Services announced that initiative...
Why Pharmaceutical Quality Cannot Be Tested Into a Product
In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...
Fifty Patients, No Registry: MVA Research Meets in London
Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...
Semaglutide Patent Expiry: What Generics Did to Prices
The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...
AI as a Research Partner for the Overstretched Life Sciences
Generative AI can lift the administrative weight of literature reviews and manuscript drafting, but only when it stays grounded in evidence and firmly under human control. The problem we know too well Every clinician who also publishes lives with a quiet collision. On...
FDA Clears First Glioma PET Imaging Drug After 2025 Rejection
The Food and Drug Administration has approved Pixclara, a glioma PET imaging drug from Telix Pharmaceuticals. Telix announced the decision in its approval announcement on 14 September 2026. The active ingredient is floretyrosine F 18, also written as 18F-FET. Telix...
Medical AI Is Getting Better. Why Is Diagnosis Getting Harder?
A radiologic study today rarely arrives alone. It comes wrapped in automated detection flags, quantitative lesion scores, an AI-drafted report, historical imaging, EHR clinical notes, and subspecialty consult requests. What it does not come wrapped in is medical AI...
Stellaromics Expands Pyxa Adoption Across the U.S. and Europe
Stellaromics Expands Pyxa® Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and Europe Icahn School of Medicine at Mount Sinai, CNAG, Karolinska Institutet, and Stanford University will apply 3D spatial multi-omics across...
Freeze-Dried Does Not Mean Pathogen-Free
Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...
Why AI Governance in Life Sciences Can’t Wait for Regulatory Clarity
The regulatory picture for AI governance in life sciences just got more confusing, not less. In June 2026, the European Union's Digital Omnibus package pushed back the EU AI Act's compliance deadline for stand-alone high-risk AI systems from August 2026 to December...
Featured Articles
Further News
Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved
Two B7-H3 ADC readouts landed in the same Seoul session on 13 September 2026. Both reported a survival win in relapsed small cell lung cancer. Both trials ran entirely in China. Neither dataset, on its own, is a filing package for the FDA, the EMA or the MHRA. Two...
Collagen Bioinks: A New Standard for 3D-Printed Tissue Constructs
Collagen bioinks have to satisfy two very different demands. They need to behave predictably during printing, and once the printing stops they must also provide an environment in which cells can organise and begin behaving like tissue. However, it’s typically the...
Autoimmune Serology Redefined: Deep B-Cell Depletion and IgG Blockade
In October 2025, the FDA approved an anti-CD20 monoclonal antibody for adults with active lupus nephritis receiving standard therapy. In the phase 3 REGENCY trial, 46.4% of patients receiving B-cell depletion plus standard therapy achieved a complete renal response at...
Radial Immunodiffusion Protocol and Troubleshooting: Why RID Still Matters
Abstract Radial immunodiffusion (RID) can look almost outdated beside ELISA, multiplex assays, and automated analytical platforms. Yet that apparent simplicity may be exactly why the method still deserves attention. RID offers a direct, visually interpretable way to...
Weekly News Roundup | 14 September 2026
Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...
Cabozantinib Salt Form Wins FDA Approval Past Malate Patents
A new cabozantinib salt form has cleared the US Food and Drug Administration. Handa Oncology announced on 11 September 2026 that the agency had granted final approval to OMCAZIO (cabozantinib) capsules. The product sits outside the patent estate Exelixis has spent...
Lenacapavir NHS Access Stalls as NICE Rejects Twice-Yearly PrEP
Lenacapavir NHS access for HIV prevention has stalled at the first hurdle. NICE published draft guidance on 9 September 2026. It does not recommend the twice-yearly injection as pre-exposure prophylaxis in England. The draft does not question whether the medicine...
The GLP-1 Divide: Who Gets the Best Weight-Loss Drugs, and Who Pays for It
A patient arrived on my ward recently with a story I have heard so many times it no longer surprises me. Her blood sugar had crept back into the danger zone, her blood pressure was climbing, and the weight she had lost over the previous year was almost all back. The...
Clinical Trials Roundup | 11 Sept 2026
Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...
Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To
Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per...
Partial Clinical Hold Lands on Opakalim Before SK Deal Closes
The US Food and Drug Administration has imposed a partial clinical hold on Biohaven’s epilepsy candidate opakalim. The hold took effect on 4 September 2026. Biohaven disclosed it in a Form 8-K filed on 10 September 2026. The measure stops new enrolment across the...
The Other Half of Innovation
What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













